CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) that stimulates your body's natural production of growth hormone and insulin-like growth factor-1 (IGF-1). This 29-amino acid peptide increases growth hormone levels by 2-10 times baseline values for up to 6 days after injection. The peptide works by binding to growth hormone-releasing hormone receptors in your pituitary gland, triggering sustained growth hormone release without suppressing your body's natural production cycles. CJC-1295 is available in two forms: CJC-1295 with DAC (Drug Affinity Complex), which provides longer duration effects, and CJC-1295 without DAC, which offers shorter, more pulsatile growth hormone release patterns. Clinical studies show significant increases in IGF-1 levels within 7 days of treatment, with patients reporting improved sleep quality, enhanced recovery, and increased lean muscle mass. As of 2026, CJC-1295 remains available through specialized peptide therapy clinics and compounding pharmacies.
Key Takeaways
- CJC-1295 increases growth hormone levels 2-10 times above baseline for extended periods
- Available in two forms: with DAC (longer acting) and without DAC (shorter acting)
- Typical dosing ranges from 1-2 mg per week for the DAC version
- Clinical benefits include improved sleep, muscle growth, and enhanced recovery
- Side effects are generally mild and include injection site reactions and potential water retention
How CJC-1295 Works in Your Body
CJC-1295 mimics your natural growth hormone-releasing hormone but with significantly enhanced stability and duration. The peptide contains four amino acid substitutions that protect it from enzymatic breakdown, allowing it to remain active in your bloodstream much longer than natural GHRH. When you inject CJC-1295, it travels to your pituitary gland and binds to GHRH receptors, triggering a cascade that releases stored growth hormone.
The DAC version extends the peptide's half-life from 30 minutes to approximately 8 days through covalent binding to albumin proteins in your blood. This creates a slow-release effect, maintaining elevated growth hormone levels for nearly a week after a single injection. The non-DAC version provides more natural pulsatile release patterns, better mimicking your body's circadian rhythm of growth hormone production.
Clinical Benefits and Research Findings
Research indicates that CJC-1295 produces measurable increases in both growth hormone and IGF-1 levels within one week of treatment initiation. A 2005 study published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 with DAC increased IGF-1 levels by 1.5 to 3-fold in healthy adults over a 28-day period. Participants experienced sustained elevation without the typical suppression seen with direct growth hormone administration.
View data table
| Category | Relative Hormone Production (%) | Detail |
|---|---|---|
| 30-39 | 92 | Optimal hormone production |
| 40-49 | 78 | Gradual decline begins |
| 50-59 | 65 | Noticeable changes |
| 60-69 | 52 | Significant decline |
| 70+ | 38 | Marked reduction |
Clinical benefits reported in studies include improved sleep architecture, with users experiencing deeper REM sleep and better sleep continuity. Lean muscle mass typically increases by 3-6% over 12 weeks of treatment, while body fat reduction of 5-10% is common. Recovery from exercise and injury shows marked improvement, making CJC-1295 popular among athletes and individuals seeking enhanced physical performance. These effects complement other peptides like BPC-157 and TB-500 for thorough recovery protocols.
Dosing Protocols and Administration
CJC-1295 with DAC is typically administered at 1-2 mg per week via subcutaneous injection, usually divided into two doses given 3-4 days apart. The peptide is often combined with growth hormone-releasing peptides like Ipamorelin or Sermorelin to enhance effectiveness through synergistic mechanisms. Injection sites rotate between the abdomen, thighs, and deltoids to prevent lipodystrophy.
Optimize your health with expert guidance
Get a personalized treatment plan after licensed provider review. Free consultation included.
Start Free Assessment →The non-DAC version requires more frequent dosing, typically 100-200 mcg administered 1-3 times daily, preferably before meals or bedtime to align with natural growth hormone release patterns. Most patients begin seeing benefits within 2-3 weeks, with peak effects occurring after 8-12 weeks of consistent use. Treatment cycles typically last 3-6 months, followed by a 4-8 week break to prevent receptor desensitization.
Side Effects and Safety Considerations
CJC-1295 suggests a favorable safety profile in clinical studies, with most adverse events being mild and transient. Common side effects include injection site reactions such as redness, swelling, or mild pain, which typically resolve within 24-48 hours. Some patients experience initial water retention or mild joint discomfort as growth hormone levels adjust.
More significant but rare side effects can include headaches, dizziness, or flu-like symptoms during the first week of treatment. Patients with a history of cancer should avoid CJC-1295, as growth factors may potentially stimulate existing malignant cells. As of 2026, pricing for pharmaceutical-grade CJC-1295 ranges from $200-400 per month depending on dosing requirements and provider selection through specialized peptide therapy clinics.
Frequently Asked Questions
How long does CJC-1295 stay in your system?
CJC-1295 with DAC has a half-life of approximately 6-8 days, meaning it remains active in your system for up to two weeks after injection. The non-DAC version has a much shorter half-life of about 30 minutes but provides growth hormone stimulation for several hours after administration. This extended duration is what makes the DAC version suitable for weekly dosing protocols.
Can you combine CJC-1295 with other peptides?
Yes, CJC-1295 is commonly stacked with other growth hormone-releasing peptides like Ipamorelin, Sermorelin, or GHRP-6 for enhanced effects. These combinations work synergistically to maximize growth hormone release through different receptor pathways. Many practitioners also combine it with recovery peptides like BPC-157 for detailed anti-aging and performance enhancement protocols.
What's the difference between CJC-1295 with and without DAC?
CJC-1295 with DAC (Drug Affinity Complex) has a modified structure that extends its half-life to 6-8 days, allowing for weekly injections and sustained growth hormone elevation. The non-DAC version has a 30-minute half-life but provides more natural, pulsatile growth hormone release patterns that better mimic your body's circadian rhythms. Both are effective, but dosing schedules differ significantly.
Is CJC-1295 legal to purchase and use?
CJC-1295 exists in a regulatory gray area as of 2026. While not FDA-approved for specific medical conditions, it's available through compounding pharmacies and peptide research companies for research purposes. Many anti-aging and hormone optimization clinics prescribe it off-label. Always consult with a qualified healthcare provider before starting any peptide therapy to ensure safe and legal access.
How quickly will I see results from CJC-1295?
Most patients notice initial improvements in sleep quality and recovery within 1-2 weeks of starting CJC-1295. Measurable increases in lean muscle mass and strength typically become apparent after 4-6 weeks of consistent use. Body composition changes, including fat reduction, are usually visible by week 8-12. Individual responses vary based on baseline hormone levels, dosing, diet, and exercise habits.
Sources
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683
- Jetton TL, Lausier J, LaRock K, et al. Mechanisms of compensatory beta-cell growth in insulin-resistant rats: roles of Akt kinase. Diabetes. 2005;54(8):2294-2304. PMID: 16046293
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295 in healthy subjects. Growth Horm IGF Res. 2006;16(5-6):310-317. PMID: 17023219
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID: 16968795
- Moulin A, Ryan J, Martinez J, Fehrentz JA. Recent developments in ghrelin receptor ligands. ChemMedChem. 2007;2(9):1242-1259. PMID: 17520596
- Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. PMID: 32257855
- Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28778697
- Clemmons DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol Metab Clin North Am. 2012;41(2):425-443. PMID: 22682639
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →